Bank of New York Mellon Corp Boosts Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Bank of New York Mellon Corp lifted its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 13.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 274,635 shares of the medical instruments supplier’s stock after acquiring an additional 31,505 shares during the quarter. Bank of New York Mellon Corp’s holdings in Harvard Bioscience were worth $783,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in HBIO. Assenagon Asset Management S.A. grew its holdings in Harvard Bioscience by 193.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock valued at $649,000 after buying an additional 150,218 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Harvard Bioscience by 38.7% in the first quarter. BNP Paribas Financial Markets now owns 75,970 shares of the medical instruments supplier’s stock worth $322,000 after purchasing an additional 21,183 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Harvard Bioscience by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock valued at $9,125,000 after acquiring an additional 49,576 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Harvard Bioscience during the 1st quarter valued at $54,000. Finally, Corsair Capital Management L.P. purchased a new stake in shares of Harvard Bioscience during the fourth quarter worth about $356,000. 80.87% of the stock is currently owned by institutional investors.

Harvard Bioscience Price Performance

HBIO stock opened at $2.75 on Monday. Harvard Bioscience, Inc. has a 1 year low of $2.50 and a 1 year high of $5.56. The company has a market cap of $119.43 million, a P/E ratio of -13.75 and a beta of 1.30. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.05 and a quick ratio of 0.94. The firm has a 50-day moving average of $2.99 and a 200 day moving average of $3.36.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.06). The business had revenue of $23.10 million during the quarter, compared to analysts’ expectations of $29.91 million. Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. On average, sell-side analysts forecast that Harvard Bioscience, Inc. will post 0.11 EPS for the current year.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.